Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK)
HKD 4.46
(0.22%)
HKD 4.46
(0.22%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 19.2 Billion CNY | -7.74% |
| 2022 | 20.81 Billion CNY | 8.93% |
| 2021 | 19.1 Billion CNY | 0.43% |
| 2020 | 19.02 Billion CNY | 24.82% |
| 2019 | 15.24 Billion CNY | 11.62% |
| 2018 | 13.65 Billion CNY | 3.53% |
| 2017 | 13.18 Billion CNY | 2.14% |
| 2016 | 12.91 Billion CNY | 6.12% |
| 2015 | 12.16 Billion CNY | 22.54% |
| 2014 | 9.93 Billion CNY | 20.06% |
| 2013 | 8.27 Billion CNY | 0.14% |
| 2012 | 8.25 Billion CNY | 3.58% |
| 2011 | 7.97 Billion CNY | -1.88% |
| 2010 | 8.12 Billion CNY | 490.36% |
| 2009 | 1.37 Billion CNY | 137.79% |
| 2008 | 578.91 Million CNY | 124.63% |
| 2007 | 257.72 Million CNY | -26.16% |
| 2006 | 349.01 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 18.57 Billion CNY | -1.6% |
| 2024 Q1 | 18.87 Billion CNY | -1.71% |
| 2023 Q4 | 19.2 Billion CNY | -4.56% |
| 2023 FY | 19.2 Billion CNY | -7.74% |
| 2023 Q1 | 20.62 Billion CNY | -0.92% |
| 2023 Q2 | 20.78 Billion CNY | 0.8% |
| 2023 Q3 | 20.12 Billion CNY | -3.21% |
| 2022 Q3 | 21.46 Billion CNY | 0.5% |
| 2022 FY | 20.81 Billion CNY | 8.93% |
| 2022 Q1 | 20.13 Billion CNY | 5.35% |
| 2022 Q4 | 20.81 Billion CNY | -3.05% |
| 2022 Q2 | 21.36 Billion CNY | 6.12% |
| 2021 Q3 | 19.26 Billion CNY | 1.52% |
| 2021 Q1 | 19.39 Billion CNY | 1.92% |
| 2021 Q2 | 18.97 Billion CNY | -2.13% |
| 2021 FY | 19.1 Billion CNY | 0.43% |
| 2021 Q4 | 19.1 Billion CNY | -0.82% |
| 2020 FY | 19.02 Billion CNY | 24.82% |
| 2020 Q3 | 18.51 Billion CNY | 11.62% |
| 2020 Q4 | 19.02 Billion CNY | 2.77% |
| 2020 Q2 | 16.58 Billion CNY | 4.66% |
| 2020 Q1 | 15.84 Billion CNY | 3.96% |
| 2019 Q3 | 14.8 Billion CNY | 5.67% |
| 2019 Q4 | 15.24 Billion CNY | 2.94% |
| 2019 Q1 | 13.44 Billion CNY | -1.55% |
| 2019 Q2 | 14.01 Billion CNY | 4.23% |
| 2019 FY | 15.24 Billion CNY | 11.62% |
| 2018 Q4 | 13.65 Billion CNY | 0.84% |
| 2018 FY | 13.65 Billion CNY | 3.53% |
| 2018 Q3 | 13.54 Billion CNY | 2.61% |
| 2018 Q2 | 13.19 Billion CNY | 1.35% |
| 2018 Q1 | 13.02 Billion CNY | -1.28% |
| 2017 Q4 | 13.18 Billion CNY | 0.5% |
| 2017 FY | 13.18 Billion CNY | 2.14% |
| 2017 Q3 | 13.12 Billion CNY | 2.71% |
| 2017 Q2 | 12.77 Billion CNY | -1.47% |
| 2017 Q1 | 12.96 Billion CNY | 0.42% |
| 2016 Q1 | 11.6 Billion CNY | -4.65% |
| 2016 FY | 12.91 Billion CNY | 6.12% |
| 2016 Q3 | 11.67 Billion CNY | 1.53% |
| 2016 Q4 | 12.91 Billion CNY | 10.65% |
| 2016 Q2 | 11.49 Billion CNY | -0.92% |
| 2015 Q2 | 10.17 Billion CNY | -1.83% |
| 2015 Q1 | 10.36 Billion CNY | 4.42% |
| 2015 Q3 | 11.5 Billion CNY | 12.97% |
| 2015 FY | 12.16 Billion CNY | 22.54% |
| 2015 Q4 | 12.16 Billion CNY | 5.81% |
| 2014 Q3 | 9.54 Billion CNY | 0.16% |
| 2014 Q2 | 9.53 Billion CNY | 14.09% |
| 2014 Q1 | 8.35 Billion CNY | 1.03% |
| 2014 Q4 | 9.93 Billion CNY | 3.99% |
| 2014 FY | 9.93 Billion CNY | 20.06% |
| 2013 Q3 | 8.11 Billion CNY | 1.89% |
| 2013 Q4 | 8.27 Billion CNY | 1.87% |
| 2013 Q1 | 8.37 Billion CNY | 1.43% |
| 2013 FY | 8.27 Billion CNY | 0.14% |
| 2013 Q2 | 7.96 Billion CNY | -4.88% |
| 2012 FY | 8.25 Billion CNY | 3.58% |
| 2012 Q4 | 8.25 Billion CNY | 3.06% |
| 2012 Q3 | 8.01 Billion CNY | 1.73% |
| 2012 Q2 | 7.87 Billion CNY | -3.64% |
| 2012 Q1 | 8.17 Billion CNY | 2.53% |
| 2011 FY | 7.97 Billion CNY | -1.88% |
| 2011 Q2 | 7.76 Billion CNY | -5.73% |
| 2011 Q3 | 7.87 Billion CNY | 1.38% |
| 2011 Q4 | 7.97 Billion CNY | 1.29% |
| 2011 Q1 | 8.23 Billion CNY | 1.36% |
| 2010 Q1 | 1.54 Billion CNY | 11.97% |
| 2010 FY | 8.12 Billion CNY | 490.36% |
| 2010 Q4 | 8.12 Billion CNY | 4.68% |
| 2010 Q3 | 7.76 Billion CNY | 3.34% |
| 2010 Q2 | 7.51 Billion CNY | 387.4% |
| 2009 FY | 1.37 Billion CNY | 137.79% |
| 2009 Q2 | 738.49 Million CNY | 0.0% |
| 2009 Q4 | 1.37 Billion CNY | 0.0% |
| 2008 FY | 578.91 Million CNY | 124.63% |
| 2007 FY | 257.72 Million CNY | -26.16% |
| 2006 FY | 349.01 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 907.46 Million HKD | -2016.16% |
| Grand Pharmaceutical Group Limited | 22.51 Billion HKD | 14.71% |
| Extrawell Pharmaceutical Holdings Limited | 1.28 Billion HKD | -1391.888% |
| Wai Yuen Tong Medicine Holdings Limited | 2.09 Billion HKD | -816.583% |
| Qianhai Health Holdings Limited | 478.11 Million HKD | -3916.468% |
| Lee's Pharmaceutical Holdings Limited | 2.89 Billion HKD | -564.325% |
| Essex Bio-Technology Limited | 2.82 Billion HKD | -579.152% |
| Tongfang Kontafarma Holdings Limited | 1.72 Billion HKD | -1011.737% |
| PuraPharm Corporation Limited | 843.96 Million HKD | -2175.386% |
| SSY Group Limited | 11.96 Billion HKD | -60.479% |
| JBM (Healthcare) Limited | 1.38 Billion HKD | -1282.837% |
| Jacobson Pharma Corporation Limited | 3.48 Billion HKD | -450.738% |
| China Resources Pharmaceutical Group Limited | 271.69 Billion HKD | 92.932% |